Edwards Lifesciences (EW) is focused on expanding its presence in strategic growth markets and accelerating its market position, mainly through new technological developments fueled by research and development investments. In this article, we’ll discuss key 2018 milestones that are expected to fuel the company’s future growth.
Transcatheter heart valve business
In fiscal 2018, Edwards Lifesciences expects a number of key product launches in its THV (transcatheter heart valve) segment. Edwards Sapien 3 Ultra, an expandable balloon system designed to reduce paravalvular leakage, is expected to be launched in Europe in early 2018 and the United States by late 2018. Boston Scientific’s (BSX) Lotus valve, Medtronic’s (MDT) Corevalve, and Abbott Laboratories’ (ABT) Portico are some competing products entering the market soon.
Edwards’s Centera, a self-expanding valve, is expected to be approved in Europe in late 2017 and launched in early 2018. The US trial of the product will be initiated in 2018.
Transcatheter mitral and tricuspid therapy trials
Edwards Lifesciences expects to complete its CLASP mitral trial in 2018, and CE mark approval is expected in fiscal 2019. Furthermore, a new trial for the Pascal system for degenerative mitral regurgitation is expected to be initiated in 2018, and a Cardioband tricuspid study is expected to be initiated in the United States in 2018. This year, the company expects Cardioband mitral platform sales of $15 million in Europe.
Surgical heart valve business
Edwards Lifesciences’ surgical heart valve business is expected to be boosted by the launch of its Harpoon system in Europe in 2018. The company expects to initiate US Harpoon trials in fiscal 2018. The launch of Inspiris Resilia in the United States and Japan in fiscal 2018 is expected to be the key growth driver for the segment.
For indirect exposure to EW stock, investors could consider the iShares Core S&P 500 ETF (IVV). EW stock comprises ~0.10% of IVV.